Urine storage disorder (urinary frequency, nocturia, urgency, urge incontinence)
Conditions
Interventions
20 active lead groups and 20 placebo lead groups
After 3 weeks of administration, take 2 weeks off and cross over 3 weeks of administration
Sponsors
Southen Knights' Laboratory Co. Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Men and women who have urinary frequency, nocturia, urgency, or urge incontinence for more than 2 months, and who have some trouble with it
Exclusion criteria
Exclusion criteria: 1 micturition disorder in treatment 2 Within 2 months from the end of treatment for micturition disorder 3 have no sense of urination 4 dysuria is the main symptom 5 Communication of the will is difficult 6 Allergies to ingredients and drugs 7 Others that the doctor in charge judged that registration to this study was inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total score for overactive bladder symptom score | — |
Secondary
| Measure | Time frame |
|---|---|
| Daytime urinary frequency, night urinary frequency, International prostate symptom score, QOL score | — |
Countries
Japan
Contacts
Public ContactKimio Sugaya
Southen Knights' Laboratory Co. Ltd. Clinical department
Outcome results
None listed